Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity of COVID-19 Vaccine on Heterologous Schedule

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participant is willing and able to give written informed consent for participation in the trial.~2. Male or Female, aged from 20 to 70 years~3. Has received one dose of the AZD1222 within 28-70 days before randomization. Evidence of this will be gathered from medical history and/or medical records including the COVID-19 vaccine registration yellow card.~4. Female participant must:~   1. Be either of non-childbearing potential, i.e. surgically sterilized (defined as having undergone hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year post-menopausal;~  2. Or, if of childbearing potential, be abstinent or agree to use medically effective contraception on enrolment continuously until 90 days after boost immunization of study intervention.~   Acceptable forms include:~   i. Implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine system ii. Established use of hormonal methods (injectable, pill, patch or ring) combined with barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository c. Have a negative pregnancy test.~5. In the Investigator's opinion, is able and willing to comply with all trial requirements.~Exclusion Criteria:~-~The participant may not enter the trial if ANY of the following apply:~1. Previous receipt of two or more COVID-19 vaccine doses~2. History of anaphylaxis, severe allergic disease or reactions likely to be exacerbated by any component of study vaccines (e.g. hypersensitivity to the active substance or any of the listed ingredients of any study vaccine). This includes latex and polyethylene glycol/macrogol (PEG)~3. Pregnancy, lactation or willingness/intention to become pregnant within 3 months post boost vaccine~4. Malignancy requiring receipt of immunosuppressive chemotherapy or radiotherapy for treatment of solid organ cancer/hematological malignancy within the 6 months prior to enrolment.~5. Bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following intramuscular injections or venipuncture.~6. Suspected or known current alcohol or drug dependency.~7. Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data.~8. Insufficient level of language to undertake all study requirements in opinion of the Investigators.~9. Known HIV antibody positive.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Heterologous group (Type: EXPERIMENTAL): 1st dose AZD1222, 2nd dose MVC-COV1901
- Homologous group (control) (Type: ACTIVE_COMPARATOR): 1st dose AZD1222, 2nd dose AZD1222

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete